Clinical significance of BRAF mutations in metastatic melanoma Journal Article


Authors: Chang, D.; Panageas, K. S.; Osman, I.; Polsky, D.; Busam, K.; Chapman, P. B.
Article Title: Clinical significance of BRAF mutations in metastatic melanoma
Abstract: Forty to eighty percent of melanoma tumors have activating mutations in BRAF although the clinical importance of these mutations is not clear. We previously reported an analysis of BRAF mutations in metastatic melanoma samples from 68 patients. In this study, we correlated patient baseline characteristics, prognostic factors, and/or clinical outcomes with the presence of BRAF mutations. No significant differences were observed in age, gender, location of primary melanoma, stage at the diagnosis, and depth of primary tumor between patients with and without BRAF mutations. Melanomas harboring BRAF mutations were more likely to metastasize to liver (P = 0.02) and to metastasize to multiple organs (P = 0.048). Neither time to progression to stage IV nor overall survival were associated with BRAF mutations. In conclusion, we observed no significant differences in clinical characteristics or outcomes between melanomas with or without BRAF mutations. Although there was an increased frequency of liver metastasis and tendency to metastasize to multiple organs in tumors with BRAF mutations, there was no detectable effect on survival. Future prospective studies should include analysis of whether BRAF mutations in melanoma tumors correlate with an increased tendency to metastasize to liver or to multiple organs. © 2004 Chang et al; licensee BioMed Central Ltd.
Keywords: adult; cancer survival; controlled study; aged; gene mutation; gene sequence; major clinical study; exon; cancer staging; antineoplastic agent; melanoma; liver metastasis; cancer regression; correlation analysis; statistical analysis; statistical significance; drug response; kaplan meier method; b raf kinase; braf mutation; metastatic melanoma; clinical significance; prognosis; human; male; female; article
Journal Title: Journal of Translational Medicine
Volume: 2
ISSN: 1479-5876
Publisher: Biomed Central Ltd  
Date Published: 2004-12-21
Language: English
DOI: 10.1186/1479-5876-2-46
PROVIDER: scopus
PMCID: PMC544849
PUBMED: 15613230
DOI/URL:
Notes: J. Transl. Med. -- Cited By (since 1996):31 -- Export Date: 16 June 2014 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. David Chang
    5 Chang
  2. Paul Chapman
    326 Chapman
  3. Katherine S Panageas
    512 Panageas
  4. Klaus J Busam
    688 Busam